Skip to content
10-Q

Quarterly Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-26-001077

← back to feed
Filed
Jun 17, 2026 11:48 AM ET
Period of report
Jun 17, 2026
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · Jun 17, 2026 207.03M sh
Cash And Equivalents 2025 · Oct 31, 2025 $1.96K
Cash And Equivalents Q3 2026 · Oct 31, 2025 $0
Cash And Equivalents Q3 2026 · Jan 31, 2025 $0
Shares Diluted Q3 2026 · Oct 31, 2025 207.03M sh
Shares Diluted Q3 2026 · Oct 31, 2025 207.03M sh
Shares Diluted Q3 2026 · Oct 31, 2024 207.03M sh
Shares Diluted Q3 2026 · Oct 31, 2024 207.03M sh
Operating Cash Flow Q3 2026 · Oct 31, 2025 −$2.81K
Operating Cash Flow Q3 2026 · Oct 31, 2024 −$12.89K
Stockholders Equity Q3 2026 · Oct 31, 2025 −$4.35M
Stockholders Equity Q3 2026 · Jul 31, 2025 −$4.21M
Stockholders Equity Q3 2026 · Apr 30, 2025 −$4.1M
Stockholders Equity Q3 2026 · Jan 31, 2025 −$4.02M
Stockholders Equity Q3 2026 · Oct 31, 2024 −$3.87M
Stockholders Equity Q3 2026 · Jul 31, 2024 −$3.7M
Stockholders Equity Q3 2026 · Apr 30, 2024 −$3.53M
Stockholders Equity Q3 2026 · Jan 31, 2024 −$3.35M
Current Liabilities Q3 2026 · Oct 31, 2025 $4.37M
Current Liabilities Q3 2026 · Jan 31, 2025 $4.03M
Total Liabilities Q3 2026 · Oct 31, 2025 $4.37M
Total Liabilities Q3 2026 · Jan 31, 2025 $4.03M
Current Assets Q3 2026 · Oct 31, 2025 $9.83K
Current Assets Q3 2026 · Jan 31, 2025 $272
Total Assets Q3 2026 · Oct 31, 2025 $16.47K
Total Assets Q3 2026 · Jan 31, 2025 $14.38K
Eps Diluted Q3 2026 · Oct 31, 2025 $0.00
Eps Diluted Q3 2026 · Oct 31, 2025 $0.00
Eps Diluted Q3 2026 · Oct 31, 2024 $0.00
Eps Diluted Q3 2026 · Oct 31, 2024 $0.00
Sga Expense Q3 2026 · Oct 31, 2025 $135.73K
Sga Expense Q3 2026 · Oct 31, 2025 $303.95K
Sga Expense restated Q3 2026 · Oct 31, 2024 $117.93K
Sga Expense restated Q3 2026 · Oct 31, 2024 $553.42K
Net Income Q3 2026 · Oct 31, 2025 −$142.52K
Net Income Q3 2026 · Oct 31, 2025 −$333.9K
Net Income Q3 2026 · Jul 31, 2025 −$110.85K
Net Income Q3 2026 · Apr 30, 2025 −$80.54K
Net Income Q3 2026 · Oct 31, 2024 −$196.29K
Net Income Q3 2026 · Oct 31, 2024 −$631.79K
Net Income Q3 2026 · Jul 31, 2024 −$218.66K
Net Income Q3 2026 · Apr 30, 2024 −$216.83K
Operating Income Q3 2026 · Oct 31, 2025 −$135.73K
Operating Income Q3 2026 · Oct 31, 2025 −$303.95K
Operating Income restated Q3 2026 · Oct 31, 2024 −$117.93K
Operating Income restated Q3 2026 · Oct 31, 2024 −$553.42K
Revenue Q3 2026 · Oct 31, 2025 $0
Revenue Q3 2026 · Oct 31, 2025 $0
Revenue Q3 2026 · Oct 31, 2024 $0
Revenue Q3 2026 · Oct 31, 2024 $0